Softwr

Healthcare · head to head

Allscripts vs Lunit

Allscripts logo

Allscripts

Healthcare

Healthcare IT solutions for care coordination

From
On request
Rated
-
Full reviewWebsite
Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Allscripts pricing is not publicly available; all quotes require direct contact with sales; Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • They diverge on capability: Allscripts covers Electronic Health Records, Lunit covers Lunit INSIGHT MMG.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Allscripts and Lunit actually diverge.

Attributes where Allscripts and Lunit differ
AttributeAllscriptsLunit
Founded1986Unknown

Identical on both: starting price (On request), pricing model (quote), free tier (No), platforms (Web), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Allscripts

  • Electronic Health Records
  • Practice Management
  • Population Health
  • Care Coordination
  • Analytics
  • HL7
  • FHIR
  • Labs

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

What people use each for

The jobs each tool is most often brought in to do.

Allscripts

  • Electronic health records and practice management for healthcare providersnot Lunit
  • Healthcare IT solutions for revenue cycle management and patient engagement (now Veradigm)not Lunit

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Allscripts
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Allscripts
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Allscripts
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Allscripts

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Allscripts

  • Pricing is not publicly available; all quotes require direct contact with sales
  • Transitioned to Veradigm brand in 2022; legacy Allscripts product line integrated into Veradigm suite

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Pricing, plan by plan

Allscripts

On request

No published plan breakdown. See the Allscripts review.

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Which should you pick?

Choose Allscripts if

  • You need electronic health records.
  • You also want practice management.
Allscripts review

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Questions people ask

Is Allscripts or Lunit better?
Neither clearly leads. Allscripts starts at On request and Lunit at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Allscripts or Lunit?
Allscripts starts at On request and Lunit at On request.
Does Allscripts or Lunit run on more platforms?
Both run on Web, so platform support will not decide this one for you.
What is Allscripts best used for?
Allscripts is most often used for electronic health records and practice management for healthcare providers, healthcare it solutions for revenue cycle management and patient engagement (now veradigm). Of those, electronic health records and practice management for healthcare providers and healthcare it solutions for revenue cycle management and patient engagement (now veradigm) are not what Lunit is typically brought in for.
What can Allscripts do that Lunit cannot?
Allscripts covers Electronic Health Records, Practice Management, Population Health, Care Coordination. Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment.

Answered from the vendors’ own pages

Allscripts: How do I obtain pricing information for Veradigm solutions?

Veradigm does not publish pricing on their website. Interested buyers must contact a Veradigm Account Executive directly or request a demo to discuss pricing and licensing options tailored to their needs.

Source
Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Allscripts: What industries does Veradigm serve?

Veradigm serves four primary market segments: Healthcare Providers, Life Sciences companies, Health Plans and Payers, and Health IT Vendors. Each segment has specialized solutions.

Source
Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Allscripts: Is there a trial available for Veradigm solutions?

Veradigm offers the option to request a demo of their solutions, which is the primary way potential customers can evaluate the platform before making a purchasing decision.

Source
Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Share

Related pages

More on Allscripts

More on Lunit

Keep looking

Other head to heads